CORRELATION BETWEEN HELICOBACTER PYLORI AND GASTRIC ADENOCARCINOMA: RETROSPECTIVE STUDY
Keywords:
Gastric Neoplasia; Gastric Adenocarcinoma, Helicobacter pyloriAbstract
INTRODUCTION: Helicobacter pylori, a gram-negative bacterium, whose infection is the most common in the world, induces the occurrence chronic inflammation in gastric mucosa, and contributes to gastric neoplasia. Gastric adenocarcinoma is the most prevalent gastric cancer (95%). Mani studies demonstrates a strong link between MALT lymphoma and Helicobacter pylori infection and others studies can correlated with adenocarcinoma. The relationship between adenocarcinoma and infection or treatment of infection was questioned. OBJECTIVE: To determine whether there is a relationship between the most frequent type of gastric cancer - adenocarcinoma - and Helicobacter pylori infection. METHODOLOGY: Retrospective, descriptive cross-sectional study of patients treated at a specialized cancer center in 2017, evaluating the diagnosis of gastric neoplasia and identification of Helicobacter pylori infection. RESULTS: Were analyzed 218 medical records of patients diagnosed with gastric cancer in 2017, 67% of whom were male. Coinciding with the literature, the great majority (98.6%) corresponded to adenocarcinoma. From these, 97 (45.1%) was investigated by Helicobacter pylori, being positive in 41 (42.3%) cases, and 95.1% of these were diagnosed with adenocarcinoma. MALT lymphoma was observed in 3 patients (1.4%). CONCLUSION: The epidemiological data evaluated are in accordance with population studies. There was no significant correlation between bacterial infection and adenocarcinoma, furthermore it was identified that is not rotine perform Helicobacter pylori detection tests on patients with gastric cancer. In addition, when the investigation is carried out in cases of gastric adenocarcinoma, a high prevalence of the bacterium is identified.
Downloads
References
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol WJG. 21 de janeiro de 2006;12(3):354–62.
3. Wang Y-H, Lv Z-F, Zhong Y, Liu D-S, Chen S-P, Xie Y. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter. fevereiro de 2017;22(1).
4. Israel DA, Peek RM. pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther. setembro de 2001;15(9):1271–90.
5. Bacteriology and epidemiology of Helicobacter pylori infection - UpToDate [Internet]. [citado 24 de março de 2020]. Disponível em: https://www.uptodate.com/contents/bacteriology-and-epidemiology-of-helicobacter-pylori-infection?search=helicobacter%20pylori&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3#H100820650
6. Helicobacter pylori and Cancer [Internet]. National Cancer Institute. [citado 14 de abril de 2018]. Disponível em: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/h-pylori-fact-sheet
7. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: High-dose proton pump inhibitors versus standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther [Internet]. julho de 2008 [citado 25 de março de 2020]; Disponível em: http://doi.wiley.com/10.1111/j.1365-2036.2008.03807.x
8. Tang H-L, Li Y, Hu Y-F, Xie H-G, Zhai S-D. Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials. Heimesaat MM, organizador. PLoS ONE. 30 de abril de 2013;8(4):e62162.
9. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 20 de maio de 2014;348(may20 1):g3174–g3174.
10. Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos M do CF, Zaterka S, et al. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol [Internet]. 16 de abril de 2018 [citado 18 de abril de 2018]; Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032018005001101&lng=en&tlng=en
11. Associação Brasileira de Câncer Gástrico - Brazilian Gastric Cancer Association - Brasil [Internet]. [citado 14 de abril de 2018]. Disponível em: http://www.abcg.org.br/?var=1
12. Zilberstein B, Malheiros C, Lourenço LG, Kassab P, Jacob CE, Weston AC, et al. Consenso brasileiro sobre câncer gástrico: diretrizes para o câncer gástrico no Brasil. ABCD Arq Bras Cir Dig São Paulo. março de 2013;26(1):2–6.
13. Gobbo AC, Helena E. FATORES GENÉTICOS E AMBIENTAIS ENVOLVIDOS NA CARCINOGÊNESE GÁSTRICA. Arq Gastroenterol. 2002;39:7.
14. INCA - CÂNCER - Tipo - Estômago [Internet]. [citado 13 de abril de 2018]. Disponível em: http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/estomago/definicao
15. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori : a population-based study. Gut. janeiro de 2018;67(1):28–35.
16. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans [Internet]. [citado 13 de abril de 2018]. Disponível em: http://monographs.iarc.fr/index.php
17. Correa P. Helicobacter pylori as a pathogen and carcinogen. J Physiol Pharmacol Off J Pol Physiol Soc. setembro de 1997;48 Suppl 4:19–24.
18. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 5 de maio de 1994;330(18):1267–71.
19. Costa RO, Hallack Neto AE, Chamone DAF, Aldred VL, Pracchia LF, Pereira J. Linfoma não Hodgkin gástrico. Rev Bras Hematol E Hemoter. fevereiro de 2010;32(1):63–9.
20. Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet Lond Engl. 24 de junho de 1995;345(8965):1591–4.
21. Vergueiro CSV, Cordiolli R, Martucci D, Peres V, Kiyamu AR, Ribeiro K de CB, et al. Soroprevalência e fatores associados à infecção pelo Helicobacter pylori em doadores de medula óssea de São Paulo. Rev Bras Epidemiol. junho de 2008;11(2):196–203.
22. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Schistosomes, Liver Flukes and Helicobacter pylori - IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 61. Vol. 61. Lyon, France; 1994.
23. Siurala M, Varis K, Wiljasalo M. Studies of Patients with Atrophic Gastritis: a 10-15-Year Follow-up. Scand J Gastroenterol. janeiro de 1966;1(1):40–8.
24. Kimura K. Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. Gastroenterology. outubro de 1972;63(4):584–92.
25. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology. setembro de 1998;115(3):642–8.
26. Persson C, Jia Y, Pettersson H, Dillner J, Nyrén O, Ye W. H. pylori Seropositivity before Age 40 and Subsequent Risk of Stomach Cancer: A Glimpse of the True Relationship? Doherty TM, organizador. PLoS ONE. 2 de março de 2011;6(3):e17404.
27. Hansson L-E, Engstrand L, Nyrén O, Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology. setembro de 1995;109(3):885–8.
28. Nomura A, Stemmermann GN, Chyou P-H, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori - Infection and Gastric Carcinoma among Japanese Americans in Hawaii. N Engl J Med. 17 de outubro de 1991;325(16):1132–6.
29. Siddique I, Al-Mekhaizeem K, Alateeqi N, Memon A, Hasan F. Diagnosis of Helicobacter pylori: Improving the Sensitivity of CLOtest by Increasing the Number of Gastric Antral Biopsies. J Clin Gastroenterol. abril de 2008;42(4):356–60.
30. Lee Y-C, Chiang T-H, Chou C-K, Tu Y-K, Liao W-C, Wu M-S, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. maio de 2016;150(5):1113-1124.e5.
31. Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, et al. Helicobacter heilmannii–associated primary gastric low-grade MALT lymphoma: Complete remission after curing the infection. Gastroenterology. maio de 2000;118(5):821–8.
32. Gravina AG, Zagari RM, Musis CD, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 7 de agosto de 2018;24(29):3204–21.
33. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. fevereiro de 2017;112(2):212–39.
34. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform. 2009 Apr;42(2):377-81.
Downloads
Published
How to Cite
Issue
Section
License
A revista é publicada sob a licença Creative Commons - Atribuição - Uso Não Comercial - Partilha nos Mesmos Termos 4.0 Internacional.
O trabalho publicado é considerado colaboração e, portanto, o autor não receberá qualquer remuneração para tal, bem como nada lhe será cobrado em troca para a publicação.
Os textos são de responsabilidade de seus autores.
É permitida a reprodução total ou parcial dos textos da revista, desde que citada a fonte.
